Connect® MM- The Multiple Myeloma Disease Registry

Inclusion Criteria: Cohort 1 and 2 * Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry * Age ≥18 years * Willing and able to provide signed informed consent * Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel Cohort 3 * Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known. * Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD). * Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy. Exclusion Criteria: Cohort 1 and 2 \- None Cohort 3 * Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM * Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry. * Patients who have discontinued from Connect® MM or another Celgene/BMS-Sponsored registry could be considered for enrollment in Cohort 3, if inclusion and exclusion criteria are met. * Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified